After Cowen & Co. and William Blair gave Rocket Pharmaceuticals (NASDAQ: RCKT) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Rocket Pharmaceuticals today and set a price target of $30.00. The company’s shares closed last Monday at $21.36, equals to its 52-week high of $21.36.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of 22.0% and a 76.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.50, a 76.2% upside from current levels. In a report released today, Robert W. Baird also reiterated a Buy rating on the stock with a $41.00 price target.
Based on Rocket Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.28 million. In comparison, last year the company had a GAAP net loss of $16.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.